Actively Recruiting
Phase 1 Randomized, Double-Blind Study of JADE201 by Subcutaneous Injection in Adults With Rheumatoid Arthritis
Led by Jade Biosciences, Inc. · Updated on 2026-10-23
36
Participants Needed
8
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1, first-in-human study to evaluate JADE201 in people with Rheumatoid Arthritis. The study aims to assess the safety, tolerability, and how the body processes the drug compared to a placebo. This randomized, double-blind trial will help lay the groundwork for future research of JADE201 in autoimmune diseases. Participants will receive a single ascending dose of JADE201 or placebo through a subcutaneous injection. The study is designed with multiple cohorts, each including six participants. JADE201 is given as a sterile solution under the skin. The trial will take place across multiple sites and is placebo-controlled to compare responses. Participants will be monitored from Day 1 through 36 weeks for safety and tolerability. Researchers will collect data on how the drug is absorbed, distributed, and eliminated in the body. Throughout the study, participants will undergo scheduled visits, lab tests, and other assessments. The study includes inpatient stays and requires adherence to treatment plans and lifestyle guidelines. The total participation may last up to 36 weeks.
CONDITIONS
Brief Title
A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
Research Team
J
Jade201 Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here